MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.64 5.81

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.55

Max

1.7

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+153.64% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-12M 640M
Eelmine avamishind	-4.17
Eelmine sulgemishind	1.64

Uudiste sentiment

By Acuity

89%

11%

325 / 349 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1. apr 2026, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1. apr 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1. apr 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1. apr 2026, 23:23 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1. apr 2026, 23:07 UTC

Tulu

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1. apr 2026, 23:02 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1. apr 2026, 22:39 UTC

Tulu

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1. apr 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1. apr 2026, 21:31 UTC

Uudisväärsed sündmused

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. apr 2026, 20:38 UTC

Tulu

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1. apr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1. apr 2026, 20:13 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1. apr 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

153.64% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 153.64%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

325 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.